Septerna (SEPN) Change in Accured Expenses (2023 - 2026)
Septerna's quarterly Change in Accured Expenses came in at -$3.5 million in Q1 2026, down 2.52% year-on-year from -$3.6 million in Q1 2025, and down 181.42% quarter-over-quarter from $4.3 million in Q4 2025.
Septerna has reported Change in Accured Expenses for 4 years, with the latest figure at -$3.5 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 2.52% year-over-year to -$3.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 146.22% YoY), and the FY2025 full-year result was $4.4 million, up 22.31% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$3.5 million, down from $4.3 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $4.3 million in Q4 2025, with the low at -$3.5 million in Q1 2026.
- Average Change in Accured Expenses over 4 years is $630200.0, with a median of $1.6 million recorded in 2023.
- Peak annual rise in Change in Accured Expenses reached 795.8% in 2025, while the deepest fall reached 113.11% in 2025.
- Tracing SEPN's Change in Accured Expenses over 4 years: stood at $1.9 million in 2023, then jumped by 56.12% to $3.0 million in 2024, then jumped by 45.36% to $4.3 million in 2025, then tumbled by 181.42% to -$3.5 million in 2026.
- The last three Change in Accured Expenses figures came in at -$3.5 million (Q1 2026), $4.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | -3.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.53 Mn |
| Mar 31, 2026 | -3.53 Mn |
| Dec 31, 2025 | 4.34 Mn |
| Dec 31, 2025 | 4.34 Mn |
| Sep 30, 2025 | 1.28 Mn |
| Sep 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | 2.19 Mn |
| Jun 30, 2025 | 2.19 Mn |
| Mar 31, 2025 | -3.45 Mn |
| Mar 31, 2025 | -3.45 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Sep 30, 2024 | 143,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | 2.05 Mn |
| Mar 31, 2024 | -1.62 Mn |
| Mar 31, 2024 | -1.62 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Dec 31, 2023 | 1.91 Mn |